The more patients you treat, the more you cure: managing cardiotoxicity in the treatment of aggressive non-Hodgkin lymphoma

Comparison of pixantrone-based regimen (CPOP-R) with doxorubicin-based therapy (CHOP-R) for treatment of diffuse large B-cell lymphoma

(2013) R. Herbrecht et al.   ANNALS OF ONCOLOGY

Treatment of the elderly patient with diffuse large B cell lymphoma

(2012) Paul A. Fields et al.   BRITISH JOURNAL OF HAEMATOLOGY

Addition of rituximab to reduced-dose CHOP chemotherapy is feasible for elderly patients with diffuse large B-cell lymphoma

(2012) Ho-Jin Shin et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Breast Cancer Treatment and Adverse Cardiac Events: What Are the Molecular Mechanisms

(2012) Laura Roca-Alonso et al.   CARDIOLOGY

Prospective International Multicenter Phase II Trial of Intravenous Pegylated Liposomal Doxorubicin Monochemotherapy in Patients With Stage IIB, IVA, or IVB Advanced Mycosis Fungoides: Final Results From EORTC 21012

(2012) Reinhard Dummer et al.   JOURNAL OF CLINICAL ONCOLOGY

Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies

(2012) Yanti Octavia et al.   JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY

Non-invasive imaging and monitoring cardiotoxicity of cancer therapeutic drugs

(2012) Ronny S. Jiji et al.   JOURNAL OF NUCLEAR CARDIOLOGY

Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1)

(2012) Norbert Schmitz et al.   LANCET ONCOLOGY

Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial

(2012) Ruth Pettengell et al.   LANCET ONCOLOGY

Replacement of conventional doxorubicin by pegylated liposomal doxorubicin is a safe and effective alternative in the treatment of non-Hodgkin's lymphoma patients with cardiac risk factors

(2011) Christian Johannes Schmitt et al.   ANNALS OF HEMATOLOGY

Diverging trends in incidence and mortality, and improved survival of non-Hodgkin's lymphoma, in the Netherlands, 1989-2007

(2011) S. A. M. van de Schans et al.   ANNALS OF ONCOLOGY

Biweekly rituximab, cyclophosphamide, vincristine, non-pegylated liposome-encapsulated doxorubicin and prednisone (R-COMP-14) in elderly patients with poor-risk diffuse large B-cell lymphoma and moderate to high ‘life threat’ impact cardiopathy

(2011) Gaetano Corazzelli et al.   BRITISH JOURNAL OF HAEMATOLOGY

Pharmacological basis of pegylated liposomal doxorubicin: Impact on cancer therapy

(2011) Alberto Gabizon et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Pharmacogenomic Prediction of Anthracycline-Induced Cardiotoxicity in Children

(2011) Henk Visscher et al.   JOURNAL OF CLINICAL ONCOLOGY

Anthracycline-Related Cardiomyopathy After Childhood Cancer: Role of Polymorphisms in Carbonyl Reductase Genes—A Report From the Children's Oncology Group

(2011) Javier G. Blanco et al.   JOURNAL OF CLINICAL ONCOLOGY

Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial

(2011) Christian Récher et al.   LANCET

Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial

(2011) Frédéric Peyrade et al.   LANCET ONCOLOGY

CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group

(2011) Michael Pfreundschuh et al.   LANCET ONCOLOGY

Non-pegylated liposomal doxorubicin (Myocet®) in patients with poor-risk aggressive B-cell non-Hodgkin lymphoma

(2011) Matteo Dell'olio et al.   LEUKEMIA & LYMPHOMA

Phase II study of the tetrahydropyranyl adriamycin–cyclophosphamide, vincristine, and prednisolone regimen combined with rituximab as first-line treatment for elderly patients with diffuse large B-cell lymphoma

(2011) Senji Kasahara et al.   LEUKEMIA & LYMPHOMA

Phase I/II study of pixantrone in combination with cyclophosphamide, vincristine, and prednisone in patients with relapsed aggressive non-Hodgkin lymphoma

(2011) Peter Borchmann et al.   LEUKEMIA & LYMPHOMA

Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly “fit” patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi

(2011) Francesco Merli et al.   LEUKEMIA & LYMPHOMA

Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines

(2010) D. Bovelli et al.   ANNALS OF ONCOLOGY

Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper

(2010) M. Aapro et al.   ANNALS OF ONCOLOGY

Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials

(2010) Lesley A Smith et al.   BMC CANCER

Anthracycline-Induced Cardiomyopathy

(2010) Daniela Cardinale et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Intermediate dose of nonpegylated liposomal doxorubicin combination (R-CMyOP) as first line chemotherapy for frail elderly patients with aggressive lymphoma

(2010) Eva Gimeno et al.   LEUKEMIA RESEARCH

Nonpegylated liposomal doxorubicin is highly active in patients with B and T/NK cell lymphomas with cardiac comorbidity or higher age

(2009) Daniel Heintel et al.   ANNALS OF HEMATOLOGY

Nonpegylated liposomal doxorubicin (MyocetTM) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EUR018 trial

(2009) S. Luminari et al.   ANNALS OF ONCOLOGY

Nonpegylated liposomal doxorubicin in the treatment of B-cell non-Hodgkin’s lymphoma: where we stand

(2009) Giuseppe Visani et al.   Expert Review of Anticancer Therapy

Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study

(2009) U. Vitolo et al.   HAEMATOLOGICA

Cardiovascular toxicity caused by cancer treatment: strategies for early detection

(2009) Renske Altena et al.   LANCET ONCOLOGY

Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults

(2008) Fotiní Dodos et al.   Clinical Research in Cardiology

Efficacy and toxicity of nonpegylated liposomal doxorubicin in breast cancer

(2008) Flora Stavridi et al.   Expert Review of Anticancer Therapy

Long-term risk of cardiovascular disease in Hodgkin lymphoma survivors-Retrospective cohort analyses and a concept for prospective intervention

(2008) Anne Andersson et al.   INTERNATIONAL JOURNAL OF CANCER

Anthracycline Cardiotoxicity: From Bench to Bedside

(2008) Luca Gianni et al.   JOURNAL OF CLINICAL ONCOLOGY

Doxorubicin Cardiotoxicity in the Elderly: Old Drugs and New Opportunities

(2008) Joseph R. Carver et al.   JOURNAL OF CLINICAL ONCOLOGY

Doxorubicin, Cardiac Risk Factors, and Cardiac Toxicity in Elderly Patients With Diffuse B-Cell Non-Hodgkin's Lymphoma

(2008) Dawn L. Hershman et al.   JOURNAL OF CLINICAL ONCOLOGY

American Society of Clinical Oncology 2008 Clinical Practice Guideline Update: Use of Chemotherapy and Radiation Therapy Protectants

(2008) Martee L. Hensley et al.   JOURNAL OF CLINICAL ONCOLOGY

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)

(2008) Michael Pfreundschuh et al.   LANCET ONCOLOGY

R-COMP 21 for frail elderly patients with aggressive B-cell non-Hodgkin lymphoma: A pilot study

(2008) Giuseppe Visani et al.   LEUKEMIA & LYMPHOMA

Addition of rituximab to chop does not increase the risk of cardiotoxicity in patients with non-Hodgkin’s lymphoma

(2008) Saadettin Kilickap et al.   MEDICAL ONCOLOGY

Detection and monitoring of cardiotoxicity—what does modern cardiology offer?

(2008) Ruxandra Jurcut et al.   SUPPORTIVE CARE IN CANCER